Literature DB >> 8169819

Polymer delivery of the active isomer of misoprostol: a solution to the intestinal side effect problem.

W E Perkins1, R G Bianchi, S J Tremont, P W Collins, J J Casler, R L Fenton, G M Wagner, M P McGrath, J C Stolzenbach, D L Kowalski.   

Abstract

SC-53450 is a new polybutadiene-based polymer system with an acid labile diisopropyl silyl ether linker to which the active isomer of misoprostol (SC-30249) is attached covalently at position C-11. It was studied in rats and dogs to define its profile of gastrointestinal effects relative to misoprostol-hydroxypropyl methylcellulose (HPMC) and the systemic availability of prostaglandin from the polymer. Results of rat studies indicate that SC-53450 has a spectrum of mucosal protective activity similar to misoprostol-HPMC, being protective against indomethacin-induced gastric, cysteamine/indomethacin-induced duodenal and indomethacin-induced lower small bowel damage. SC-53450, in contrast to misoprostol-HPMC, was not diarrheagenic in the rat when administered intragastrically. The observation that SC-53450 is more than 4 times more potent than misoprostol-HPMC suggests the possibility of sustained gastric availability of the prostaglandin SC-30249. SC-53450 exhibited gastric antisecretory activity in histamine-stimulated gastric fistula dogs and protected against acidified aspirin-induced gastric damage in normal fasted beagles. Rat and dog experiments indicate that little, if any, polymer-derived prostaglandin is available systemically, suggesting SC-53450 will have reduced abuse potential in abortion induction. SC-53450 is a potential candidate to replace the present misoprostol formulation in the marketplace for the prevention of nonsteroidal anti-inflammatory drug-induced gastric damage.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8169819

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  1 in total

1.  Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles.

Authors:  Matthew C Parrott; Mathew Finniss; J Chris Luft; Ashish Pandya; Anuradha Gullapalli; Mary E Napier; Joseph M DeSimone
Journal:  J Am Chem Soc       Date:  2012-04-30       Impact factor: 15.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.